We are live on ! Find out more
BOLD

Audentes Therapeutics, Inc
BOLD

Delisted

BOLD was delisted on the 14th of January, 2020.

Back to rankings

49 hedge funds and large institutions have $272M invested in Audentes Therapeutics, Inc in 2016 Q3 according to their latest regulatory filings, with 49 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed
Holders
49
Holders Change
+49
Holders Change %
–
% of All Funds
1.31%
Holding in Top 10
2
Holding in Top 10 Change
+2
Holding in Top 10 Change %
% of All Funds
0.05%
New
49
Increased
–
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

1
O
OrbiMed
New York
+$72.9M
2
VVM
Versant Venture Management
California
+$27.4M
3
DM
Deerfield Management
New York
+$21.3M
4
RG
Redmile Group
California
+$13.9M
5
RCM
RA Capital Management
Massachusetts
+$10.7M

Top Sellers

No sellers this quarter
Name Holding Trade Value Shares
Change 		Change in
Stake
O
1
OrbiMed
New York
$85.5M +$72.9M +4,801,638 New
VVM
2
Versant Venture Management
California
$32.2M +$27.4M +1,806,832 New
DM
3
Deerfield Management
New York
$25M +$21.3M +1,403,653 New
RG
4
Redmile Group
California
$14.9M +$13.9M +916,626 New
RCM
5
RA Capital Management
Massachusetts
$12.6M +$10.7M +707,426 New
AllianceBernstein
6
AllianceBernstein
Tennessee
$10.1M +$8.59M +565,838 New
T. Rowe Price Associates
7
T. Rowe Price Associates
Maryland
$10M +$8.8M +579,681 New
RSCM
8
Rock Springs Capital Management
Maryland
$8.64M +$7.36M +485,000 New
CAM
9
Cormorant Asset Management
Massachusetts
$8.01M +$6.82M +449,660 New
Adage Capital Partners
10
Adage Capital Partners
Massachusetts
$7.87M +$6.71M +442,000 New
VMI
11
VHCP Management II
New York
$7.27M +$6.96M +458,882 New
Franklin Resources
12
Franklin Resources
California
$6.54M +$5.57M +367,100 New
Fidelity Investments
13
Fidelity Investments
Massachusetts
$6.23M +$5.31M +350,000 New
Jennison Associates
14
Jennison Associates
New York
$5.32M +$4.53M +298,586 New
Vanguard Group
15
Vanguard Group
Pennsylvania
$4.28M +$3.64M +240,061 New
EAM
16
Eventide Asset Management
Massachusetts
$4.01M +$3.41M +225,000 New
BA
17
BlackRock Advisors
Delaware
$3.56M +$3.04M +200,072 New
BFA
18
BlackRock Fund Advisors
California
$2.74M +$2.33M +153,762 New
SFM
19
Sphera Funds Management
Israel
$2.67M +$2.28M +150,000 New
JP Morgan Chase
20
JP Morgan Chase
New York
$2.33M +$1.98M +130,566 New
Alyeska Investment Group
21
Alyeska Investment Group
Illinois
$2.17M +$1.85M +121,735 New
BG
22
BlackRock Group
United Kingdom
$1.82M +$1.55M +102,058 New
FCMI
23
Foresite Capital Management III
California
$1.19M +$1.01M +66,553 New
PPA
24
Parametric Portfolio Associates
Washington
$1.04M +$887K +58,416 New
OA
25
Omega Advisors
New York
$816K +$695K +45,800 New
1
2

BOLD Hedge Fund Activity: Q3 2016 in Review

49 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Audentes Therapeutics, Inc (BOLD) for Q3 2016, worth a combined $272M.

Buyers outnumbered sellers: 49 funds opened new BOLD positions and 0 closed out — a net gain of 49 holders — while 0 added to existing stakes and 0 trimmed.

The largest buyer was OrbiMed, opening a new position worth an estimated $72.9M.

  • 49 institutional investors held Audentes Therapeutics, Inc (BOLD) as of Q3 2016, up from 0 in Q2 2016.
  • Funds reported $272M of Audentes Therapeutics, Inc stock for Q3 2016.
  • 49 funds opened new Audentes Therapeutics, Inc positions in Q3 2016 and 0 closed out, a net change of +49 holders.
  • The largest Audentes Therapeutics, Inc buyer in Q3 2016 was OrbiMed, an estimated $72.9M added.

Based on aggregated 13F filings for Q3 2016.